SUPER GELKYD® 3920 WDA 49

ARCHITECTURAL COATINGS

ARKEMA COATING RESINS

Product Application details

SUPER GELKYD® 3920 WDA 49 is a urethane - urea modified thixotropic alkyd that has been developed for use in decorative coatings, especially exterior woodstains. It can be used as sole binder for high structured systems and in combination with long or medium oil alkyds.

The resin is supplied in low aromatic high flash white spirit to enable the formulation of coatings that do not require adverse environmental labelling. SUPER GELKYD® 3920 WDA 49 can be formulated with polar solvents, alkyds (whatever their polarity) and a wide range of difficult pigments, which are not compatible with polyamide-based products.

Polymer Type

Thixotropic Alkyd

Sales Specifications

Solid Content at 125°C, % (ISO 3251)	48 - 50
Viscosity at 25°C, mPa.s (at 10000 s-1) (ISO 3219)	240 - 300
Gel strength at 25°C, g/cm (Intern. method LQ 27)	120 - 220

Other Characteristics¹

/olatile Low aromatic high flash white spirit	
Flash point, °C (ISO 3679)	64
Density / Specific Gravity at 25°C, g/ml (ISO 2811)	0.90
Type of fatty acid	Linoleic rich

¹ The data provided for these properties are typical values, intended only as guides, and should not be construed as sales specifications

ACTIVATION

To achieve full structure it is necessary to "activate" the SUPER GELKYD® by adding polar solvent, normally at the end of paint manufacture. Glycols and glycol ethers have been found to be effective activating solvents. Propylene glycol is recommended and should be used at a typical level of 2-3% calculated on total solid resin content. Higher levels may adversely affect the final structure. It is important to add the glycol under very low shear at the end of the paint manufacturing process. Propylene glycol can lead to long-term corrosion of steel containers. It is recommended that lacquer lined cans are used.

Formulation Guidelines

DRIERS

SUPER GELKYD® 3920 WDA 49 requires metal driers to accelerate the autoxidation process. A suitable combination of driers for use in systems containing SUPER GELKYD® 3920 WDA 49 is: 0.06% cobalt, 0.09% zirconium and 0.1% calcium calculated as metals on solid resin. Depending on the formulation (clear, pigmented, etc...) and on the application, the loading of each drier may be increased or reduced in order to achieve the appropriate drying/hardness profile. The use of an anti-skinning agent is essential to prevent in-can skinning of the finished product.

Product Safety	Please refer to the corresponding Safety Data Sheet.
Storage & Handling	SUPER GELKYD® 3920 WDA 49 should be stored indoors in the original, unopened and undamaged container, in a dry place at a temperature not exceeding 30°C. Exposure to direct sunlight should be avoided. In the above mentioned storage conditions the shelf life of the resin will be 6 months from the shipping date

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, Arkema expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in medical devices applications that are in contact with the body or circulating bodily fluids (http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html) Arkema has designated medical grades to be used for such medical device applications. Products that have not been designated as medical grades are not authorized by Arkema for use in medical device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in medical device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies). It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

